GTx (NASDAQ: GTXI) is one of 196 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its rivals? We will compare GTx to similar businesses based on the strength of its risk, valuation, analyst recommendations, earnings, profitability, dividends and institutional ownership.

Insider & Institutional Ownership

9.1% of GTx shares are owned by institutional investors. Comparatively, 47.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 41.2% of GTx shares are owned by company insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for GTx and its rivals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GTx 0 0 0 0 N/A
GTx Competitors 785 2925 6378 144 2.57

As a group, “Biotechnology & Medical Research” companies have a potential upside of 10.38%. Given GTx’s rivals higher possible upside, analysts clearly believe GTx has less favorable growth aspects than its rivals.


This table compares GTx and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
GTx N/A -192.51% -145.17%
GTx Competitors -3,680.68% -416.66% -48.22%

Valuation and Earnings

This table compares GTx and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
GTx N/A -$26.47 million -4.68
GTx Competitors $207.14 million -$2.51 million 0.26

GTx’s rivals have higher revenue and earnings than GTx. GTx is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

GTx has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Comparatively, GTx’s rivals have a beta of 1.67, indicating that their average stock price is 67% more volatile than the S&P 500.


GTx rivals beat GTx on 6 of the 9 factors compared.

About GTx

GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with metastatic and high-risk non-metastatic castration resistant prostate cancer (CRPC). Its product candidate, Enobosarm, for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer (TNBC), is in Phase II clinical development-stage.

Receive News & Stock Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related stocks with our FREE daily email newsletter.